Human respiratory syncytial virus (RSV) is a virus that causes respiratory tract infections. It is a major cause of lower respiratory tract infections and hospital visits during infancy and childhood. A prophylactic medication (not a vaccine) exists for preterm (under 35 weeks gestation) infants, infants with certain congenital heart defects (CHD) or bronchopulmonary dysplasia (BPD), and infants with congenital malformations of the airway. Treatment is limited to supportive care (for example C-PAP), including oxygen therapy.
Garg, R; Latimer, L; et al. The respiratory syncytial virus fusion protein formulated with a novel combination adjuvant induces balanced immune responses in lambs with maternal antibodies. VACCINE 33:1338-1344(2015).
De Clercq, E; et al. Chemotherapy of respiratory syncytial virus infections: the final breakthrough. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS 45:234-237(2015).